Share Review - Alembic Pharmaceuticals

For 3Q FY 2012, Alembic Pharmaceuticals is expected to post net sales of Rs.389  cr
and net profit of Rs.31.9  cr. Growth would mainly be driven by exports sales. The
company’s OPM is expected to come in at 14.0% during the period.

Maintain  Buy recommendation on the stock with a target price of Rs. 77.

Review by Angel Broking
Share:

No comments:

Post a Comment

Popular Posts

Blog Archive

Recent Posts

Featured Post

BSE releases list of 25 stocks available for T+0 settlement starting March 28, 2024

BSE releases list of 25 stocks available for T+0 settlement starting March 28, 2024